LFB a republié ceci
I am delighted to have had the opportunity to present the perspective of G5 Santé on the global situation of the healthcare industry and to propose recommendations during my interview with Roxane Höck from PharmaBoardroom. A central priority for G5 Santé is to strengthen France’s position as both a competitive and attractive hub for healthcare innovation and industrial investment. France has the scientific talent, industrial base, and political momentum to succeed; provided we align regulation, investment, and innovation behind a coherent strategy. We have at G5 Santé continued to advocate for mechanisms that reinforce France’s health and industrial sovereignty. We also published a study focused on improving the efficiency of the French healthcare system. The question we asked was simple: in a context of constrained public finances, how can we continue to fund the arrival of new health innovations? In the current global geopolitical context, the need to implement bold measures to enhance France’s and Europe’s industrial competitiveness has never been more critical. This urgency is amplified by the increasingly assertive protectionist stance of the United States and the rapid strides China is making in innovation. In such a context, it is imperative that Europe, and France in particular, strengthens its position and champions a robust industrial agenda at the European level. As we often say at G5 Santé: “Choisir la France, soigner le monde,” choosing France means contributing to global health. The time has come to turn that principle into a policy reality. Alexandre Merieux, Pierre Boulud bioMérieux, David Hale Guerbet, David Loew Ipsen, Jacques Brom LFB, Eric Ducournau Laboratoires Pierre Fabre, Paul Hudson, Audrey Duval, MD Sanofi, Olivier Laureau Servier, #JeanFrédéricChibret Laboratoires Théa #souverainety #healthindustry
"Europe is losing the global innovation race" - France's pharma CEOs speak out Didier Véron speaks for the CEOs of France's eight largest healthcare companies as head of G5 Santé. When he sat down with PharmaBoardroom's Roxane Höck, his message was urgent: Europe is losing the global innovation race. The numbers are brutal. 40% of medicines approved by European regulators aren't available in France. Average access delays exceed 500 days. The "safeguard clause" tax alone hits €1.6 billion annually. "While the US announces $200 billion in health investments, global healthcare CEOs were notably absent from France's Choose France summit," Véron told us. Meanwhile, China represents 30-40% of global biotech transactions. The US is threatening 25% tariffs on pharmaceutical imports. Europe's response? More price cuts and regulatory burden. Véron's solution is Article 75 - a provision that lets pricing factor in manufacturing location. Reward companies that build in France instead of treating it as just another market. "Choisir la France, soigner le monde" - choosing France means contributing to global health. But the window for action is narrowing fast. Get the full picture at: https://lnkd.in/dv2kBcMC